Kyowa Kirin discontinues ongoing trials of rocatinlimab
Kyowa Kirin discontinues ongoing trials of rocatinlimab
Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation for moderate-to-severe AD, prurigo nodularis, and moderate-to-severe asthma.
